Author: admin

Budget airline Ryanair is planning to increase its “personal bag” size by 20% as the EU brings in a new standard.

Passengers will be allowed to take an item such as a handbag or laptop bag measuring up to 40cm x 30cm x 20cm in the cabin without paying an extra fee. It should weigh less than 10kg, and fit “under the seat in front you.”

The new size represents a 20% increase in volume from the current maximum dimensions.

This will mean that Ryanair accepts free bags one third bigger than the new EU minimum size limit.

Ryanair said the new free bag size would come into effect in the coming weeks as its bag size measuring devices were adjusted to the new standard.

It’s current maximum bag size is 40cm x 25cm x 20cm, which already has a greater volume than the new European standard of 40cm x 30cm x 15cm.

Ryanair declined to say why it was giving passengers a larger carry-on bag allowance.

The size is still less generous than rival budget airline Easyjet, which allows a free underseat bag of 45cm x 36cm x 20cm (including wheels and handles) weighing up to 10kg.

Wizz Air allows one cabin bag as big as Ryanair’s new limits – 40cm x 30cm x 20cm, with the same weight limit of 10kg.

BA has a slightly smaller limit for an under-seat laptop bag or handbag of 40cm x 30cm x 15cm, but passengers are allowed to take a larger cabin bag as well free of charge, subject to a maximum weight of 23kg.

The EU has been working with airlines to agree a minimum free bag size, so that frequent travellers can purchase one piece of luggage and be confident it would be accepted by multiple airlines.

The rule applies to airlines based in the EU – which includes Easyjet, Ryanair and Wizz Air – but airlines are of course free to accept larger bags if they choose.

Confusion about the different minimum sizes has caused problems for passengers, who have sometimes been faced with unexpected extra fees when airlines said their bags didn’t match the specified dimensions.

Last month the transport committee of the European parliament voted to give passengers the right to an extra piece of free hand luggage weighing up to 7kg. The proposed rule would still have to be passed by the wider European parliament.

Passengers should confirm baggage rules with their airlines directly.

The addition of durvalumab (Imfinzi) to perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) did not lead to differences in overall health-related quality of life (QOL), patient function, or symptom burden vs placebo plus FLOT in patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma, according to an analysis of patient-reported outcomes (PROs) from the phase 3 MATTERHORN trial (NCT04592913).¹

Data presented at the 2025 ESMO Gastrointestinal Cancers Congress demonstrated that no clinically meaningful deterioration in global health score (GHS)/QOL, physical function, or role function was observed for durvalumab plus FLOT (n = 467) vs placebo plus FLOT (n = 459) at 3 months following the completion of treatment. Similarly, PROs were comparable between the 2 arms in terms of symptom burden, including dysphagia, eating restrictions, anxiety, dry mouth, taste, hair loss, body image, weight loss, fatigue, and appetite loss.

PROs recorded over the course of treatment showed that there was no clinically meaningful deterioration in GHS/QOL in either arm overall. Notably, clinically relevant deterioration in GHS/QOL—defined as a decrease of at least 10 points—occurred in both arms during cycles 4 and 5, but this improved to a decrease of less than 10 points by cycle 5 in both groups.

Additionally, there was no relevant difference in time to deterioration (TTD) in PROs between the 2 treatment groups. The median TTD for GHS/QOL was 13.86 months (95% CI, 11.24-19.98) in the durvalumab arm vs 13.60 months (95% CI, 10.68-16.46) in the placebo arm (HR, 0.90; 95% CI, 0.76-1.07). Regarding physical function, the median TTD was 13.70 months (95% CI, 10.94-17.84) and 11.93 months (95% CI, 9.26-15.38) for the durvalumab and placebo regimens, respectively (HR, 0.89; 95% CI, 0.75-1.05). For role function, the median TTD was 10.12 months (95% CI, 7.98-11.66) for those given durvalumab and 8.34 months (95% CI, 7.23-10.68) for those given placebo (HR, 0.90; 95% CI, 0.76-1.05).

“This [PRO] analysis supports the positive risk:benefit profile of perioperative durvalumab [plus] FLOT in patients with localized gastric and GEJ adenocarcinoma,” lead study author Salah-Eddin Al-Batran, MD, of Krankenhaus Nordwest, University Cancer Center (UCT) Frankfurt and Frankfurt Institute of Clinical Cancer Research in Germany, said in a presentation of the data.

Revisiting Efficacy Data From MATTERHORN

Data presented at the 2025 ASCO Annual Meeting showed MATTERHORN met its primary end point, with patients treated with durvalumab plus FLOT achieving a statistically significant improvement in event-free survival (EFS) compared with those treated with placebo plus FLOT (HR, 0.71; 95% CI, 0.58-0.86; P < .001).² The median EFS was not reached (NR; 95% CI, 40.7-NR) for the durvalumab arm vs 32.8 months (95% CI, 27.9-NR) in the placebo arm.

The median overall survival (OS) was NR (95% CI, NR-NR) for patients in the durvalumab group vs 47.2 months (95% CI, 45.1-NR) for those in the placebo arm (HR, 0.78; 95% CI, 0.62-0.97; P = .025). Although this difference was not statistically significant, Al-Batran noted that data from the final OS analysis are pending.¹

MATTERHORN Background and PRO Analysis

The global, randomized, double-blind, placebo-controlled study enrolled patients with stage II to IVA gastric or GEJ adenocarcinoma who had no evidence of metastases, received no prior therapy, and had an ECOG performance status of 0 or 1.

Patients were randomly assigned 1:1 to receive neoadjuvant FLOT in combination with durvalumab or placebo, followed by surgery and adjuvant FLOT plus durvalumab or placebo, then 10 cycles of durvalumab or placebo monotherapy. In both the neoadjuvant and adjuvant combination portions, FLOT was given for 4 doses both before and after surgery, and durvalumab or placebo were given for 2 doses both before and after surgery.

Stratification factors included geographic region (Asia vs non-Asia), clinical lymph node status (positive vs negative), and PD-L1 expression (tumor area proportion [TAP] score <1% vs TAP ≥1%).

Along with the EFS primary end point, key secondary end points comprised OS and pathological complete response rate. Secondary PRO end points included TTD and change from baseline in function and symptoms.

The median age at baseline was 62 years (range, 26-84) in the durvalumab arm and 63 years (range, 28-83) in the placebo arm. Most patients in both arms were male (durvalumab, 69%; placebo, 75%), not from Asia (81%; 81%), had an ECOG performance status of 0 (71%; 77%), had gastric adenocarcinoma (68%; 67%), had non-T4 disease (75%; 75%), had node-positive disease (69%; 70%), had a PD-L1 TAP of at least 1% (90%; 90%), had an intestinal histology (52%; 50%), and did not have microsatellite instability–high disease (64%; 65%).

Baseline PROs were similar between the durvalumab and placebo arms in terms of function as evaluated by the EORTC QLQ-C30 questionnaire and function per the EORTC QLQ-STO22 + IL38 questionnaire. “We can also see that patients were mildly symptomatic compared [with patients with] metastatic [disease], reflecting the ECOG performance status for patients in this study,” Al-Batran explained.

Furthermore, compliance rates for PROs were high in both arms over the course of the study. After utilizing the EORTC QLQ-C30 and EORTC QLQ-STO22 + IL38 questionnaires at baseline, PROs were recorded with these forms from cycles 2 through 14. Compliance rates for both questionnaires never dipped below 76.3% in either arm at any assessment point during treatment, and the vast majority of cycles had compliance rates above 80% in both groups.

Safety Data

Safety findings, which were also presented at the ASCO Annual Meeting in June, showed that any-grade adverse effects (AEs) were reported in 99% of patients in both arms. AEs possibly related to study treatment occurred in 95% of patients in both groups. Grade 3/4 AEs were observed in 72% of patients in the durvalumab arm vs 71% of patients in the placebo group, and the rates of grade 3/4 AEs possibly related to treatment were 60% and 59%, respectively. Serious AEs were reported at rates of 48% for the durvalumab regimen vs 44% for the placebo regimen.

AEs led to discontinuation of any study treatment in 30% of patients in the durvalumab arm vs 23% of those in the control arm. Durvalumab was discontinued in 10% of patients due to AEs, whereas 6% of patients discontinued placebo. AEs led to FLOT discontinuation in 25% and 20% of patients, respectively. Fatal AEs occurred in 5% of patients in the durvalumab arm vs 4% of patients in the placebo arm. The rates of fatal AEs possibly related to durvalumab or placebo were 1% and less than 1%, respectively. AEs leading to death possibly related to FLOT occurred in 1% and less than 1% of patients, respectively.

Any-grade immune-mediated AEs (irAEs) occurred in 23% of patients in the durvalumab group vs 7% of those in the placebo arm. Grade 3/4 irAEs were reported in 7% and 4% of patients, respectively. AEs prevented surgery in 1% of patients in the durvalumab group vs less than 1% of patients in the placebo group. Surgery was delayed due to AEs in 2% and 3% of patients, respectively.

Disclosures: Al-Batran reported serving in advisory roles for AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly Germany, and Merck Sharp & Dohme; receiving funding from AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Eli Lilly Germany, Eurozyto, Federal Ministry of Education and Research, German Cancer Aid, German Research Foundation, Immutep, Ipsen, Merck Sharp & Dohme, Roche, Sanofi, and Vifor Pharma; having an ownership interest in Frankfurter Institut für Klinische Krebsforschung; and serving in a speakers’ bureau for AlO GmbH, Bristol Myers Squibb, Eli Lilly Germany, and MCI Group.

References

1. Al-Batran S-E, Wainberg ZA, Muro K, et al. Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. Presented at: 2025 ESMO Gastrointestinal Cancer Congress; July 2-5, 2025; Barcelona, Spain. Abstract LBA4.
2. Janjigian Y, Al-Batran S-E, Wainberg Z, et al. Event-free survival (EFS) in MATTERHORN: a randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC). J Clin Oncol. 2025;43(suppl 17):LBA5. doi:10.1200/JCO.2025.43.17_suppl.LBA5